Tasman Therapeutics enters partnership with Osmind to advance R-107 for depressive disorders: San Francisco Thursday, August 13, 2026, 17:00 Hrs [IST] Tasman Therapeutics, a clini ...
SAN FRANCISCO, CA and TORONTO, ON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the "Company" or "Claritas") today outlined the Company’s plans ...
SAN FRANCISCO and TORONTO, April 01, 2021 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (formerly Kalytera Therapeutics, Inc.) (TSX VENTURE: KLY and OTC: KALTF) (the "Company" or "Claritas") ...
Type: Liquid prodrug of nitric oxide, administered via a single intramuscular injection. Status: Kalytera said July 16 it was granted an exclusive, worldwide license to develop and commercialize R-107 ...
In a recent study published in the journal Nature Medicine, an international team of researchers evaluated the efficacy, safety, and tolerability of extended-release ketamine tablets (R-107) in adult ...
Tasman Therapeutics today announced a multi-year strategic partnership with Osmind, the market leader in technology and real-world evidence for psychiatry, to support its R-107 Ketamine program. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results